Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., filed a Form 4 on September 1, 2026, disclosing the sale of 15,000 shares of common stock pursuant to a previously adopted Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: 15,000 shares of Xeris Biopharma Holdings common stock disposed of on September 1, 2026.
  • Weighted average price: $8.4872 per share, with individual transactions ranging from $8.390 to $8.600, inclusive.
  • 10b5-1 plan: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by McCulloch on September 4, 2025.
  • Direct ownership following transaction: 1,639,208 shares held directly after the reported sale.
  • Indirect holdings: 25,000 shares held indirectly by spouse, with McCulloch disclaiming beneficial ownership except to the extent of his pecuniary interest.

McCulloch's Sale Details and Remaining Ownership in Xeris Biopharma

According to the filing, Kevin McCulloch, serving as President and Chief Operating Officer of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), disposed of 15,000 shares of the company's common stock on September 1, 2026. The transaction was coded as a sale (S) and carried out under a Rule 10b5-1 trading plan that McCulloch had adopted on September 4, 2025, as noted in the filing's explanation of responses.

The filing reported a weighted average sale price of $8.4872 per share. Individual transactions within the sale occurred at prices ranging from $8.390 to $8.600, inclusive. The filing states that McCulloch "undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."

Following the reported transaction, McCulloch directly holds 1,639,208 shares of common stock. The filing also discloses 25,000 shares held indirectly by his spouse. McCulloch disclaims beneficial ownership of those indirectly held shares "except to the extent of his pecuniary interest therein," and the filing notes that inclusion of those shares "shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose." The form was signed by Beth Hecht as Attorney-in-Fact on September 1, 2026.

What Was Disclosed

The filing reports a single open-market sale of 15,000 common shares by Xeris Biopharma's President and COO at a weighted average price of $8.4872, executed under a pre-established 10b5-1 plan, leaving him with 1,639,208 directly held shares.